Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma

Kensei Tobinai, Michinori Ogura, Yukio Kobayashi, Toshiki Uchida, Takashi Watanabe, Takashi Oyama, Dai Maruyama, Tatsuya Suzuki, Masakazu Mori, Masanobu Kasai, Damien Cronier, James E. Wooldridge, Minori Koshiji
  • Cancer Science, January 2011, Wiley
  • DOI: 10.1111/j.1349-7006.2010.01809.x

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1111/j.1349-7006.2010.01809.x

In partnership with: